IMBRUVICA (Ibrutinib)-140 mg

IMBRUVICA (Ibrutinib) is a targeted therapy, works against cancerous B lymphocytes, a type of white blood cells. It inhibits the function of Bruton’s tyrosine kinase (BTK), an enzyme that promotes the survival of B lymphocytes and their migration to the organs where these cells normally divide.

It is used in the treatment of ;

• Chronic graft-versus-host (cGVHD) disease after failure of one or more prior lines of systemic therapy.
• Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
• Mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
• Waldenstrom’s macroglobulinemia